newsfilter
← Latest News
GlobeNewswire·

OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly

KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ:OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial